Clinical Outcomes of a Cohort Study on Patients with CD40L Deficiency
Abstract
Background/objectives: CD40 ligand (CD40L) deficiency is an X-linked form of hyper Immunoglobulin M syndrome (XHIGM) that is caused by mutations of CD40Lgene. The aim of the present study was to investigate the clinical and molecular basis of this disorder in a group of Iranian patients with a long period of follow-up.
Methods: A total number of 21 patients diagnosed with X-HIGM, who were referred to and followed up at Children’s Medical Center (Pediatrics Center of Excellence affiliated to Tehran University of Medical Sciences, Tehran, Iran), were included in this retrospective cohort study. The medical and immunologic evaluations of patients were followed by mutation analysis to confirm the diagnosis.
Results: The median age of all participants was 7.50 (4.87-16.25) years. The median age at the time of disease onset was 8.00 (6.00-13.50) months. The majority of patients showed their first manifestation before 4 years of age. The median age of diagnosis was 23.00 (12.50-48.00) months, with a median diagnostic delay of 9.00 (1.50-28.00) months. Anemia was the most common hematologic manifestation, occurring in 71.4% of the patients. The median serum IgM concentration was 206 (82-335) mg/dL. Elevated IgM levels were observed in fifteen patients based on age-references and six patients had normal IgM levels. The mutation analysis among patients with the CD40L mutations revealed 15 missense, 5 frameshift-nonsense, and 1 splice-site mutation. Eight patients (38%) died during the study period. Respiratory infection such as pneumonia were the main cause of death in the 5 patients.
Conclusion: Earlier diagnosis of X-HIGM may provide effective management and lead to patients’ survival and better quality of life. Moreover, using whole-exome sequencing for detection of patients with HIGM phenotype is strongly recommended to differentiate it from intrinsic humoral immunity defects and to initiation the appropriate therapeutic procedures and management.
2. Leven EA, Maffucci P, Ochs HD, Scholl PR, Buckley RH, Fuleihan RL, et al. Hyper IgM syndrome: a report from the USIDNET registry. Journal of clinical immunology. 2016;36(5):490- 501.
3. Allen RC, Armitage RJ, Conley ME, Rosenblatt H, Jenkins NA, Copeland NG, et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science. 1993;259(5097):990-3.
4. Winkelstein JA, Marino MC, Ochs H, Fuleihan R, Scholl PR, Geha R, et al. The X-linked hyperIgM syndrome: clinical and immunologic features of 79 patients. Medicine. 2003;82(6):373-84.
5. Delbari MT, Cheraghi T, Yazdani R, Fekrvand S, Delavari S, Azizi G, et al. Clinical Manifestations, Immunological Characteristics and Genetic Analysis of Patients with Hyper-Immunoglobulin M Syndrome in Iran. International archives of allergy and immunology. 2019:1-12.
6. Hollenbaugh D, Grosmaire L, Kullas C, Chalupny NJ, Braesch‐Andersen S, Noelle R, et al. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co‐ stimulatory activity. The EMBO journal. 1992;11(12):4313-21.
7. Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proceedings of the National Academy of Sciences. 1992;89(14):6550-4.
8. Miga A, Masters S, Gonzalez M, Noelle R. The role of CD40-CD154 interactions in the regulation of cell mediated immunity. Immunological investigations. 2000;29(2):111-4.
9. Noelle RJ. CD40 and its ligand in host defense. Immunity. 1996;4(5):415-9.
10. Tsai H-Y, Yu H-H, Chien Y-H, Chu K-H, Lau Y-L, Lee J-H, et al. X-linked hyper-IgM syndrome with CD40LG mutation: two case reports and literature review in Taiwanese patients. Journal of Microbiology, Immunology and Infection. 2015;48(1):113-8.
11. Yazdani R, Fekrvand S, Shahkarami S, Azizi G, Moazzami B, Abolhassani H, et al. The hyper IgM syndromes: Epidemiology, pathogenesis, clinical manifestations, diagnosis and management. Clinical Immunology. 2018.12. Qamar N, Fuleihan RL. The hyper IgM syndroms Clinical reviews in allergy & immunology. 2014:46 (2):120-30.
13. Chavoshzadeh Z, Mahdaviani SA, Momen T, et al. Fourth Update on the Iranian National Registry of Primary Immunodeficiencies: Integration of Molecular Diagnosis. Journal of clinical immunology. 2018;38(7):816-32.
14. Aghamohammadi A, Mohammadinejad P, Abolhassani H, Mirminachi B, Movahedi M, Gharagozlou M, et al. Primary immunodeficiency disorders in Iran: update and new insights from the third report of the national registry. Journal of clinical immunology. 2014;34(4):478-90.
15. Miller S, Dykes D, Polesky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic acids research. 1988;16(3):1215.
16. Abolhassani H, Chou J, Bainter W, Platt CD, Tavassoli M, Momen T, et al. Clinical, immunologic, and genetic spectrum of 696 patients with combined immunodeficiency. Journal of Allergy and Clinical Immunology. 2018;141(4):1450-8.
17. Abolhassani H, Aghamohammadi A, Fang M, Rezaei N, Jiang C, Liu X, et al. Clinical implications of systematic phenotyping and exome sequencing in patients with primary antibody deficiency. Genetics in Medicine. 2019;21(1):243.
18. Tang WJ, An YF, Dai RX, Wang QH, Jiang LP, Tang XM, et al. Clinical, molecular, and T cell subset analyses in a small cohort of Chinese patients with hyper-IgM syndrome type 1. Human immunology. 2014;75(7):633-40.
19. Ouadani H, Ben-Mustapha I, Ben-ali M, Benkhemis L, Largueche B, Boussoffara R, et al. Novel and recurrent AID mutations underlie prevalent autosomal recessive form of HIGM in consanguineous patients. Immunogenetics. 2016;68(1):19-28.
20. Levy J, Espanol-Boren T, Thomas C, Fischer A, Tovo P, Bordigoni P, et al. Clinical spectrum of Xlinked hyper-IgM syndrome. The Journal of pediatrics. 1997;131(1 Pt 1):47-54.
21. Winkelstein JA, Marino MC, Ochs H, Fuleihan R, Scholl PR, Geha R, et al. The X-linked hyperIgM syndrome: clinical and immunologic features of 79 patients. Medicine. 2003;82(6):373-84.
22. Davies EG, Thrasher AJ. Update on the hyper immunoglobulin M syndromes. British journal of haematology. 2010;149(2):167-80.
23. Hirbod-Mobarakeh A, Aghamohammadi A, Rezaei N. Immunoglobulin class switch recombination deficiency type 1 or CD40 ligand deficiency: from bedside to bench and back again. Expert review of clinical immunology. 2014;10(1):91-105.
24. Mavroudi I, Papadaki V, Pyrovolaki K, Katonis P, Eliopoulos AG, Papadaki HA. The CD40/CD40 ligand interactions exert pleiotropic effects on bone marrow granulopoiesis. Journal of leukocyte biology. 2011;89(5):771-83.
25. Rawat A, Mathew B, Pandiarajan V, Jindal A, Sharma M, Suri D, et al. Clinical and molecular features of X-linked hyper IgM syndrome-An experience from North India. Clinical immunology (Orlando, Fla). 2018;195:59-66.
| Files | ||
| Issue | Vol 2, No 3 (2019) | |
| Section | Original Article | |
| DOI | https://doi.org/10.22034/igj.2019.199002.1020 | |
| Keywords | ||
| Primary immunodeficiency Hyper-immunoglobulin M syndrome Class Switch Recombination Genetic diagnosis Pneumonia | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
